Island Pharmaceuticals (ASX:ILA) Cash-to-Debt : 1.92 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Island Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.92.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Island Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Island Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ASX:ILA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.92 Med: No Debt Max: No Debt
Current: 1.92

During the past 3 years, Island Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 1.92. And the median was No Debt.

ASX:ILA's Cash-to-Debt is ranked worse than
68.65% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs ASX:ILA: 1.92

Island Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Island Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Island Pharmaceuticals Cash-to-Debt Chart

Island Pharmaceuticals Annual Data

Trend

Jun21

Jun22

Jun23

Cash-to-Debt

No Debt

Island Pharmaceuticals Semi-Annual Data
	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			No Debt	No Debt	31.79	No Debt	1.92

Competitive Comparison of Island Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Island Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Island Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Cash-to-Debt falls into.

Island Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Island Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Island Pharmaceuticals had no debt ⁽¹⁾.

Island Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.976	/	(0.508	+	0)
	=	1.92

Island Pharmaceuticals (ASX:ILA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Island Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals (ASX:ILA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.

Island Pharmaceuticals (ASX:ILA) Headlines

No Headlines